Philippe Moreau, Tamás Masszi, Norbert Grzasko, Nizar J Bahlis, Markus Hansson, Ludek Pour, Irwindeep Sandhu, Peter Ganly, Bartrum W Baker, Sharon R Jackson, Anne-Marie Stoppa, David R Simpson, Peter Gimsing, Antonio Palumbo, Laurent Garderet, Michele Cavo, Shaji Kumar, Cyrille Touzeau, Francis K Buadi, Jacob P Laubach, Deborah T Berg, Jianchang Lin, Alessandra Di Bacco, Ai-Min Hui, Helgi van de Velde, Paul G Richardson
BACKGROUND: Ixazomib is an oral proteasome inhibitor that is currently being studied for the treatment of multiple myeloma. METHODS: In this double-blind, placebo-controlled, phase 3 trial, we randomly assigned 722 patients who had relapsed, refractory, or relapsed and refractory multiple myeloma to receive ixazomib plus lenalidomide-dexamethasone (ixazomib group) or placebo plus lenalidomide-dexamethasone (placebo group). The primary end point was progression-free survival...
April 28, 2016: New England Journal of Medicine